HIGHLIGHTS
SUMMARY
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease that can have a significant impact on the quality of life of affected patients and their families. There are only scant data on the safety of dupilumab and other systemic therapies in AD patients with comorbid conditions, including kidney disorders, as well as elderly patients, also because such patients are usually excluded from randomized clinical trials. The authors describe three male adult patients with severe AD and kidney disease who were safely and successfully treated with a standard dosage of dupilumab (600 mg induction . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.